title: Blood lipids and stroke: what more can we do besides reducing low-density lipoprotein cholesterol?
abstract: Statin therapy has became the most important advance in stroke prevention since the introduction of aspirin and blood pressure-lowering therapies. Other lipid-modifying drugs have been less successful in reducing the incidence of stroke, but because of evidence for the use of triglyceride-lowering drugs and treatments that raise concentrations of high-density lipoprotein (HDL) cholesterol, further investigations are needed, particularly in patients with an atherogenic dyslipidemia profile (high triglycerides and low HDL cholesterol levels). Furthermore, beyond reducing low-density lipoprotein cholesterol and possibly improving other lipids fractions in patients who are at high risk of stroke, the present review shoes that lipid-modifying drugs might have neuroprotective effects that should also be further explored.
authors.affiliation: Department of Medical Pharmacology, University Lille-North of France. dominique.deplanque@univ-lille2.fr
authors.forename: Dominique
authors.initials: D
authors.lastname: Deplanque
authors.forename: Pierre
authors.initials: P
authors.lastname: Amarenco
mesh_terms: D002986:Clinical Trials as Topic; D011345:Fenofibrate / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D020300:Intracranial Hemorrhages / Q000517:prevention & control; D008055:Lipids / Q000097:blood*; D018696:Neuroprotective Agents / Q000627:therapeutic use; D018570:Risk Assessment; D012307:Risk Factors; D055502:Secondary Prevention; D020521:Stroke / Q000097:blood* / Q000517:prevention & control*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008055:Lipids; D018696:Neuroprotective Agents; D011345:Fenofibrate